SYMPOSIUM - LIESHMANIASIS
Year : 2010 | Volume
: 2 | Issue : 2 | Page : 167--176
Drug resistance in leishmaniasis
Jaya Chakravarty, Shyam Sundar
Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221 005, India
Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221 005
The treatment options of leishmaniasis are limited and far from satisfactory. For more than 60 years, treatment of leishmaniasis has centered around pentavalent antimonials (Sb v ). Widespread misuse has led to the emergence of Sb v resistance in the hyperendemic areas of North Bihar. Other antileishmanials could also face the same fate, especially in the anthroponotic cycle. The HIV/ visceral leishmaniasis (VL) coinfected patients are another potential source for the emergence of drug resistance. At present no molecular markers of resistance are available and the only reliable method for monitoring resistance of isolates is the technically demanding in vitro amastigote-macrophage model. As the armametrium of drugs for leishmaniasis is limited, it is important that effective monitoring of drug use and response should be done to prevent the spread of resistance. Regimens of simultaneous or sequential combinations should be seriously considered to limit the emergence of resistance.
|How to cite this article:|
Chakravarty J, Sundar S. Drug resistance in leishmaniasis.J Global Infect Dis 2010;2:167-176
|How to cite this URL:|
Chakravarty J, Sundar S. Drug resistance in leishmaniasis. J Global Infect Dis [serial online] 2010 [cited 2020 Apr 5 ];2:167-176
Available from: http://www.jgid.org/text.asp?2010/2/2/167/62887
Leishmaniasis is a disease caused by the protozoan parasites belonging to the genus Leishmania. There are an estimated 12 million humans infected, with an incidence of 0.5 million cases of the visceral form of the disease and 1.5 to 2.0 million cases of the cutaneous form of the disease.  Ninety per cent of the annual global burden of visceral leishmaniasis (VL) cases occurs in India, Nepal, Bangladesh, and Brazil. , In India, about 100,000 cases of VL are estimated to occur annually. Of these, the state of Bihar accounts for more than 90% of cases.  Similarly, 90% of all cases of CL occur in Afghanistan, Brazil, Peru, Saudi Arabia, and Syria, while 90% of all cases of mucocutaneous leishmaniasis (MCL) occur in Bolivia, Brazil, and Peru. 
Most forms of leishmaniasis are zoonotic, human beings affected only secondarily, but two species of Leishmania can maintain arthroponotic, human-human cycle.  These species are L. donovani, the species responsible for VL in the Indian subcontinent and East Africa, and L. tropica, which is responsible for CL in the old World.
The emerging HIV/VL coinfection is locked in a vicious circle of mutual reinforcement. It has been reported from more than 35 countries, initially, most of these cases were from South Western Europe now there is increasing incidence in Africa (Ethiopia, Sudan). , The HIV/VL coinfected patients are another potential source for the emergence of drug resistance. , These patients have a high parasite burden and weak immune response. They respond slowly to treatment and have high relapse rates. , Further, reports of transmission of the infection via needle-sharing in HIV /VL coinfected patients in southern Europe threaten to convert an apparently zoonotic disease into the anthroponotic form. ,,
There is a regional variation in response to antileishmanial drugs and thus recommendations for treatment of VL vary in different regions. Pentavalent antimonial compounds (Sb v ) remain the treatment of choice in Africa, South America, Bangladesh, Nepal and India (except North Bihar) at the dose of 20 mg/kg/day parenterally for 28-30 days. In the Mediterranean basin liposomal amphotericin B (L-AmB) is the treatment of choice for immunocompetent patients  The drug of choice for the treatment of HIV/VL coinfection is an extended course of L-AmB. ,
In the recent years, new therapies have developed for VL e.g. L-AmB, oral miltefosine, and paramomycin. Although a number of drugs have now become available for the treatment of leishmaniasis each have limitation of either parenteral administration (except miltefosine), toxicity, long course of treatment, need for hospitalization and close monitoring. The treatment of cutaneous leishmaniasis may be local or systemic depending on the natural history of sores, the causative species, the possibility of mucosal dissemination, and the cosmetic and functional implications. Pentavalent antimonials are the treatment of choice where systemic treatment is indicated. Treatment of CL has improved through the introduction of topical formulations of paromomycin. , Whereas the immunomodulator immiquimod in combination with meglumine antimoniat has not shown any additional benefit.  Response to miltefosine is also seen in some forms of CL. 
At the same time as these new therapies are becoming available the standard pentavalent antimonials (Sb v ) are being threatened by development of resistance. There is increasing awareness that drug treatment can be complicated by drug-host immune response interaction, variation in pharmacokinetics and variation in the sensitivity of Leishmania species to drugs.
The immune status of leishmaniasis patients has long been known to affect drug efficacy. This is of particular importance in relation to pentavalent antimonial treatment of diffuse cutaneous leishmaniasis (DCL)  and co infections with HIV in the visceral form, , where there is an absence of a specific T-cell mediated immune response and mutual exacerbation of infection.
The pharmacokinetic properties of an antileishmanial drug can also determine efficacy as sitamaquine an 8-minoquinoline is well distributed to the liver  and is being considered for treatment of VL, whereas the antifungal itraconazole (a triazole) is well distributed to the skin  and has been used for the treatment of CL. Significant differences were observed between patients in the elimination rate of antimonials and area under the curve analysis suggested that differences in the length of exposure to antimony could influence clinical response in CL treatment. 
Moreover, there are about 20 species of Leishmania known to be infective to humans and there is variation in intrinsic sensitivity between Leishmania species to several drugs.
Pentavalent antimonials sodium stibogluconate and meglumine antimonate (Glucantime) remain the first line treatment for all clinical forms of leishmaniasis, despite the variable therapeutic response and the growing concern of treatment failure. One of the reasons behind the variable response could be intrinsic difference in species sensitivity to the drug, Studies using the amastigote-macrophage model, L. donovani and L. brasiliensis were found to be three- to fivefold more sensitive to sodium stibogluconate than L. major, L.tropica, and L. Mexicana.,,
This was also observed in a controlled clinical trial in Guatemala, which compared the cure rate to antimonials in CL caused by different species; sodium stibogluconate was seen to produce a significantly higher cure rate in patients with L. braziliensis (96%) lesions than those with L. mexicana (57%). 
History of Antimony Resistance
Although the selection of resistant Leishmania has long been a part of laboratory studies, it is only in the past 20 years that acquired resistance has become a clinical threat. The first indication of drug resistance came from North Bihar, in the early 80s, of about 30% patients not responding to the prevailing regimen of Sb v , which was a small daily dose (10 mg/kg; 600 mg maximum) for short duration (6 to 10 day).  Then two 10-day courses with a 10-day interval therapy with sodium antimony gluconate were recommended by an expert committee leading to a marked improvement in the cure rates up to 99%.  However, in1984, it was seen that with 20 mg/kg (maximum 600 mg) for 20 days, 86% of patients were cured and cure rate with 10mg/kg was quite low.  In the same year, the WHO expert committee recommended that pentavalent antimony be used in doses of 20 mg/kg up to a maximum of 850 mg for 20 days, and a repetition of similar regimen for 20 days in cases of treatment failures. The WHO recommendations was evaluated a few years later by Thakur et al. and it was reported that only 81% of patients were cured by this regimen, although with an extension of the treatment for 40 days, 97% of patients could be cured.  Three years later, the same group noted a further decline in cure rate to 71% after 20 days of treatment, and recommended extended duration of treatment in nonresponders.  However, by early 90s, extending the therapy to 30 days could cure only 64% of patients in a hyperendemic district of Bihar.  In two studies carried out under strictly supervised treatment schedules, it was observed that only about one-third of the patients could be cured with the currently prevailing regimen. , The incidence of primary unresponsiveness was 52%, whereas 8% of the patients relapsed. Incidentally, only 2% of the patients from the neighboring state of (Eastern) Uttar Pradesh (UP) failed treatment.  There are reports of antimony resistance spreading to the Terai regions of Nepal, especially from the district adjoining the hyperendemic areas of Bihar, where up to 30% of the patients seems to be unresponsive, though in Eastern Nepal a 90% cure rate has been reported.  These studies confirmed that a high level of antimony resistance existed in Bihar, whereas it was still effective in surrounding areas.
There had been speculations whether Indian Leshmania donovani had become truly refractory to Sb v or resistance occurred because of the inadequate doses being used in Bihar. In a study to determine whether acquired drug resistance was present in Bihar, L. donovani isolates were taken from responders and nonresponders. In vitro amastigote-macrophage assay showed that isolates from patients who did respond to sodium stibogluconate treatment were threefold more sensitive, with 50% effective doses (ED 50 ) around 2.5 μg Sb/ml compared to isolates from patients who did not respond (ED 50 around 7.5 μg Sb/ml).  The significant differences in amastigote sensitivity supported the concept of acquired resistance in Bihar.
The reasons for the emergence of resistance were the widespread misuse of the drug. Sb v was freely available in India, both qualified medical practitioners and unqualified quacks used the drug and this unrestricted availability of the drug led to rampant misuse. Almost 73% patients consulted unqualified practitioners first, most of them did not use the drug appropriately.  It was a common practice to start with a small dose and gradually build up to the full dose over a week; it was also advocated to have drug free periods to minimize the toxicity, especially renal toxicity and physicians split the daily dose in two injections. These practices resulted in build-up of subtherapeutic blood levels and increased tolerance of parasites to Sb v .
Almost half of the patients, receiving pentamidine as a second-line drug, had not received adequate antimony treatment before being labeled as refractory to Sb v . These facts indicated large-scale misuse of antileishmanial drugs in Bihar, contributing to development of drug resistance. There were several manufacturers of Sb v in India, and quality of products were inconsistent, resulting in occasional batches being substandard and toxic, this added to the problems associated with Sb v therapy causing serious toxicity and deaths related to the drug. 
Another reason for the growing resistance to Sb v in India while it still remained sensitive all over the world could be due to the fact that leishmaniasis usually has zoonotic transmission except in the Indian subcontinent and East Africa where the transmission is largely anthroponotic. In an anthroponotic cycle once Sb v resistance gets established, it spreads exponentially and organisms sensitive to the drug get eliminated quickly, whereas the drug-resistant parasites continue to circulate in the community.
HIV/VL coinfected patients is another subset who respond poorly to Sb v , as the drug needs an intact immune system to be effective, and the response is not as good as in immunocompetent patients. Initial parasitological cure with Sb v could be as low as 37%,  and eventually most of the initially cured patients tend to relapse. Thus, they are a potential source for emergence of drug resistance.
In CL the response is not as predictable, because there is considerable variation in sensitivity to Sb v among primary isolates from untreated patients with cutaneous leishmaniasis, which correlates with patients' response to treatment.  Except Bihar, primary resistance is quite uncommon, but resistance develops in patients with VL, CL, and MCL who have relapsed. Chances of response to further courses of antimonials diminish once there is a relapse after the initial Sb v treatment.  In L. infantum isolates taken from VL patients in France drug-sensitive strains (ED50 ofin vitro conditions (ED50 of>70 μg/ml) corresponded to clinical failures and in vitro sensitivity of strains decreased progressively in relapsing patients treated with meglumine . 
Mechanism of Resistance
The mechanism of action of antimonials are still unclear. The unique thiol metabolism of Leishmania is thought to play a pivotal role in the mechanism of action of antimonial drugs. In these parasites, the major low-molecular-mass thiol is trypanothione (T[SH] 2 ).  Key functions of this essential metabolite include maintenance of thiol redox homeostasis, as well as defense against chemical  and oxidative stress.  Antimonial drugs are administered as pentavalent antimony [Sb [V] ), a prodrug requiring conversion to the trivalent form [Sb(III)], before becoming biologically active. However, the site of reduction (host macrophage, amastigote, or both) and mechanism of reduction (enzymatic or nonenzymatic) remain unclear. , Sb(III) interferes directly with thiol metabolism, decreasing thiol-buffering capacity in drug-sensitive Leishmania donovani by inducing rapid efflux of intracellular T[SH] 2 and GSH.  Sb(III) also inhibits T[SH] 2 reductase in intact cells, resulting in the accumulation of the disulfide forms of both T[SH] 2 (T[S] 2 ) and GSH. These two mechanisms act synergistically against Leishmania parasites, leading to a lethal imbalance in thiol homeostasis.
Some studies have reported apoptosis in Sb (III)-treated amastigotes involving DNA fragmentation and externalization of phosphatidylserine on the outer surface of the plasma membrane. , However, these effects do not involve the classical caspase mediated pathway  and do not meet the more recent stringent definition of apoptosis. 
Extensive research has been done to elucidate the mechanism of resistance to antimonials,however, the exact mechanism is still not known Most of our understanding of mechanism of resistance to antimony stems from work on laboratory mutants, mostly of Leishmania tarentolae, in which resistance has been introduced in vitro by the selective pressure of heavy metals, principally arsenite and which are found to be cross resistant to Sb(III) While evaluating resistance mechanisms in the field, it should be kept in mind that L. tarentolae is quite different in sensitivity to antimony as compared to species that infect mammals. Further, the promastigote cell lines selected for Sb v resistance may have been selected for resistance to an m-chlorocresol preservative which also have antileishmanial properties instead of Sb v as promastigotes are not sensitive to pentavalent antimonials. Alternatively, Sb v preparations could be partially reduced to Sb (III) due to prolonged storage at acidic pH or in culture media containing thiols. Some of the possible mechanisms which can lead to antimony resistance in Leishmania are being mentioned.
Diminished biological reduction of Sb v to Sb (III) has been demonstrated in L. donovani amastigotes resistant to sodium stibogluconate.  It is not known whether this mechanism occurs in clinical isolates at present. Although recently an arsenate reductase gene (LmACR2) and a thiol-dependent reductase (TDRl) from L. major has been identified their role in drug resistance is not known. ,
In prokaryotes and eukaryotes (yeast and mammalian), aquaglyceroporins (AQPs) are known to transport trivalent metalloids. Aquaglyceroporins from L. major (LmAQPl) have recently been demonstrated to mediate uptake of Sb(III) in Leishmania spp. and overexpression of aquaglycoporin 1 in drug resistant parasites is seen to render them hypersensitive to Sb(III). 
Increased levels of trypanothione(TSH) have been observed in some lines selected for resistance to Sb(III) or arsenite.  This is due to increased levels of the rate-limiting enzymes involved in the synthesis of glutathione (glutamylcysteine synthetase, GCS) and polyamines (ornithine decarboxylase, ODC) the two precursor metabolites to trypanothione. , The modulation of TSH levels by using specific inhibitors of g-GCS or ODC could revert the resistance in mutants. 
The ATP-binding cassette (ABC) protein PGPA (renamed as MRPA). has been assumed to play a major role on metal resistance in Leishmania. PGPA is a member of the multidrug-resistance protein (MRP) family, a large family of ABC transporters, several of which are implicated in drug resistance.  The PGPA gene has been shown to be frequently amplified in Leishmania cells that are selected for resistance to arsenite- or antimony-containing drugs. , Legare et al. observed that PGPA is localized in small vesicles near flagellar pocket and these are responsible for intracellular sequestration of arsenic/antimony-thiol conjugates, thereby conferring arsenite and antimonite resistance.  In a study on Leishmania infantum amastigote parasites selected for resistance to Sb(III) the expression of three genes coding for the ABC transporter MRPA (PGPA), S-adenosylhomocysteine hydrolase, and folylpolyglutamate synthase were found to be consistently increased. Transfection of the MRPA gene was shown to confer sodium stibogluconate resistance in intracellular parasites which could be reverted by using the glutathione biosynthesis-specific inhibitor buthionine sulfoximine. 
However, in an isolate from Sb v refractory patients no amplified PGPA sequence could be detected, instead a novel 1.254-kb gene whose locus is on chromosome 9 involved in protein phosphorylation was identified.  Transfection experiments established that this isolated fragment confers antimony resistance to wild-type Leishmania species. It remains to be established whether this recently identified gene sequence can be used as a probe in the clinic to identify antimony-resistant clinical isolates on the Indian subcontinent.
Pentamidine is another antileishmanial which suffered the same fate as Sb v in North Bihar. It was the first drug to be used in patients refractory to Sb v and cured 99% of these patients initially however in the next two decades its efficacy dwindled to approximately 70% of patients. , Its use in VL was ultimately abandoned due to its decreased efficacy and serious toxicities. However, it has been used to good effect in treatment of both Old and New World CL and MCL. Fewer injections over short periods result in a high cure rate with minimum toxicity. In CL caused by L. guyanensis, 89% of cases were cured with two injections (4 mg/kg) given 48 h apart, and 80% of remaining patients were cured by a second course with minimum adverse effects.  In Colombian CL, four doses of 2 mg/kg of pentamidine on alternate days cured 84% patients, and four injections of 3mglkg cured 94%.  Its efficacy has also been demonstrated in Brazilian CLand MCL. ,,
The antileishmanial mechanism of action of pentamidine, are still not clearly known, however possible mechanism include inhibition of polyamine biosynthesis, DNA minor groove binding, and effect on mitochondrial inner membrane potential.  Pentamidine-resistant promastigote clones of L. donovani and L.amazonensis were shown to have 18- and 75-fold reduced uptakes, respectively, and increased efflux.  Specific transporters for pentamidine uptake have been characterized and might have a role in resistance. , Wild-type promastigotes accumulate more pentamidine in the mitochondrion in comparison to resistant cells. It is suggested that less organelle accumulation makes far more drug available for efflux. 
Amphotericin B a polyene antibiotic is now being used as a first line therapy in areas with Sb v resistance. It has excellent cure rates (~100%) at doses of 0.75-1.00 mg/kg for 15 infusions on daily or alternate days. It has been used extensively in Bihar with uniformly good results. ,
Lipid-associated amphotericin preparations are as effective as conventional amphotericin B, and have negligible adverse reactions. The dose requirement of liposomal amphotericin B varies from region to region; while in the Indian subcontinent a small dose induces high cure rates a higher dose in needed for Eastern Africa, the Mediterranean region and Brazil. ,, This higher efficacy of liposomal amphotericin B against L. donovani than L. infantum/L. chagasi infections is probably related more to parasite load and host immune status pathology than species sensitivity. 
To determine the mechanism of resistance, a resistant clone of L. donovani promastigotes was selected through a stepwise increase in amphotericin B concentration in culture. Resistant promastigotes showed a significant change in plasma membrane sterol profile by gas chromatography-mass spectrometry, ergosterol being replaced by a precursor, cholesta-5, 7, 24-trien-3β-ol. This probably results from a defect in C-24 transmethylation due to loss of function of S-adenosyl-L-methionine-C24-∆-sterolmethyltransferase (SCMT). In L. donovani promastigotes two transcripts of the enzyme have now been characterized, one of which was absent in the amphotericin B-resistant clone, the other overexpressed but without a splice leader sequence which would prevent translation.  These studies have been performed with promastigotes and their importance in the intracellular amastigote is not known.
Clinical resistance to amphotericin B is rare. Nevertheless, with the increasing use of amphotericin B, especially in lipid formulations which have longer half life, the possibility of resistance cannot be ignored. There are two small inconclusive studies on the emergence of amphotericin B resistance in L. infantum/HIV-infected cases in France. One study failed to find a change in sensitivity in promastigotes derived from isolates taken before and after the treatment of one patient.  In contrast, a decrease in sensitivity was observed in isolates taken over several relapses from another patient. 
Miltefosine, an alkyl phospholipid is the first oral agent approved for the treatment of leishmaniasis. At the recommended doses (100mg daily for patients weighing ≥25 kg and 50mg daily for those weighing  It has a long-terminal half-life, which ranges between 150 and 200 h. About four half-lives (25-33 days) are required to reach more than 90% clearance of the plateau levels (at steady-state). Thus, subtherapeutic levels may remain for some weeks after a standard course of treatment. This characteristic might encourage the emergence of resistance. 
In vitro studies shows variation in the sensitivities of both promastigote and amastigote stages of L. donovani, L. major, L. tropica, L. aethiopica, L. mexicana,and L. panamensis to miltefosine.  In all assays L.donovani was the most sensitive species and L. major was the least sensitive species. Studies on clinical isolates using a murine macrophage-amastigote model have confirmed the high sensitivity of L. donovani from both Sb-sensitive and Sb resistant patients from Nepal and lack of sensitivity of L. braziliensis and L. guyanensis isolates from patients in Peru.  This variability in sensitivity reflects differences in intrinsic susceptibility however it could have an important impact on clinical outcome. The greatest clinical significance is seen in Central and South America where distribution of L. mexicana, L. amazonensis, L. panamensis, L. braziliensis overlap. The clinical relevance of this finding was observed for CL by Soto et al. in Colombia, where L. panamensis is common, the cure rate was 91%, whereas in Guatemala, where L. braziliensis and L. mexicana are common, the cure rate was 53%. 
Although the exact mechanism of action of miltefosine is not clear it is known to induce apoptosis-like death in L. donovani based on observed phenomena such as cell shrinkage, nuclear DNA condensation, DNA fragmentation into oligonucleosome-sized fragments and phosphatidylserine exposure. ,
In experimental L. donovani strains resistant to miltefosine, the mechanism of resistance was found to be due to a >95% reduced accumulation of 14 C-labeled miltefosine. A defect in the internalization step must have occurred in the resistant line as binding to the parasite plasma membrane, efflux of preloaded drug and metabolism were similar in sensitive and resistant parasites.  A novel plasma membrane P-type transporter (LdMT gene) from the aminophospholipid translocase subfamily has been observed to be responsible for the uptake of both miltefosine and glycerophospholipids into L. donovani promastigotes. Two alleles with single distinct point mutations on this transporter were shown to be responsible for the reduced uptake.  The localization of LdMT and thus its activity depends on the presence of a specific beta subunit, LdRos3 which belongs to the CDC50/Lem3 protein family. Both proteins are mutually dependent for their function and their localization at the plasma membrane.  However, whether the inactivation of LdMT or LdRos3 produce resistant parasites in in vivo situations is not known. Another mechanism for resistance could be an increase in drug efflux, mediated by the overexpression of the ABC transporter P-glycoprotein, Previously it had been shown that multidrug-resistant L.tropica lines that over express a P-glycoprotein are less sensitive to miltefosine.  In contrast, P-glycoprotein overexpression was not observed in the 40 μM-miltefosine-resistant promastigotes. 
Paromomycin, an aminoglycoside-aminocyclitol antibiotic, has been used for the treatment of VL in a parenteral formulation and CL in both topical and parenteral formulations. In the phase III trial of Paromomycin in the Indian subcontinent, it was shown to be noninferior to amphotericin B and was approved by the Indian government in August 2006 for the treatment of patients with visceral leishmaniasis.  Topical preparations of paromomycin, a soft paraffin-based ointment containing 15% of paromomycin and 12% methylbenzethonium chloride (MBCL), are effective against both Old World as well as New World CL. , Variation in sensitivity has been seen in both experimental models and clinical cases of CL, as lesions caused by L. major treated with paromomycin ointment resolved faster and more completely than lesions caused by L. amazonensis and L. panamensis.
A more indepth in vitro analysis on the sensitivity of amastigotes in a murine macrophage model showed that L. major and L. tropica were more sensitive than L. braziliensis and L. mexicana isolates and L. donovani showed intermediate sensitivity.  Clinical resistance with this drug in VL is not known as it has not been used extensively. However, following a 60-day parenteral course for treatment of CL in two L. aethiopica cases, isolates taken from relapsed patients were three- to fivefold less sensitive to the drug after treatment than isolates taken before treatment in an amastigote-macrophage assay. 
The mechanisms of action of paromomycin in Leishmania spp. is exactly not known however mitochondrial ribosomes and induction of respiratory dysfunction and mitochondrial membrane depolarization have been implicated. , In studies on selected populations of promastigotes, resistance was related to decreased drug uptake in L. donovani. In a recent study, the mitochondrial membrane potential was significantly decreased after 72 hours of exposure to paromomycin indicating that this organelle might be the ultimate target of the drug. Both cytoplasmic and mitochondrial protein synthesis were inhibited, however, the drug induced reduction in membrane potential and inhibition of protein synthesis were less pronounced in the resistant strain as compared to the wild-type. A line selected for resistance to the drug showed reduced paromomycin accumulation associated with a significant reduction in the initial binding to the cell surface. 
Sitamaquine, a 4-methyl-6-methoxy-8-aminoquinoline has limited clinical use and no reported resistance. Relatively poor efficacy compounded with nephrotoxicity suggests that this drug cannot be used as monotherapy in VL. 
Azole-like ketaconazole and triazoles, intraconazole, and fluconazole have antileishmanial effects.  One placebo-controlled trial on the treatment of CL showed that L. mexicana infections (89%) were more responsive than L. braziliensis infections (30%) to ketoconazole indicating an intrinsic differences in sensitivity of Leishmania species to azoles.  These drugs has limited clinical use and clinical resistance is not known.
Strategies to Combat Drug Resistance
In a study to detect the factors leading to antimony resistance in Indian VL it was observed that only 26% were treated according to the WHO guidelines, 42% did not take the drug regularly and 36% stopped the drug on their own initiative.  Similar concerns were raised for miltefosine when in a preliminary data from a phase IV trial in India involving domiciliary treatment with miltefosine and weekly supervision showed doubling of the relapse rate.  These findings suggests that monitoring therapy is imperative to prevent development of resistance. The directly observed treatment strategy (DOTS) for tuberculosis has been a big success and either a parallel or integrated with DOTS system could be evolved for leishmaniasis. This will lead to better compliance, completion of the treatment course and ultimately prevent resistance.
Free distribution of drugs
The high cost of the antileishmanial drugs coupled with easy, over the counter availability often leads to under dosing and incomplete treatment. This has been the major factor for antimony resistance and could lead to resistance to other drugs as well especially the novel oral agent miltefosine. Considering that majority of the population cannot afford to purchase and complete a full course of treatment it is recommended that antileishmanials should be made available free of cost to be distributed through public and/ or private health care providers like antitubercular and antiretroviral drugs, and antileishmanial drugs should be withdrawn from the open market.
The growing resistance of the parasite to antileishmanial drugs suggests that the currently used monotherapy needs to be reviewed. Multidrug combination therapy has been used successfully in tuberculosis, leprosy and malaria. The rationale behind combination therapy are increased activity through use of compounds with synergistic or additive activity, preventing the emergence of drug resistance, lower dose requirement thereby reducing chances of toxic side effects and cost, and increased spectrum of activity.
Recently, a study showed that an single infusion of Liposomal Amphotericin B (at a dose 3.75 mg/kg - 5mg/kg) followed by a brief (7, 10 or 14 days) self-administered course of miltefosine had excellent cure rates making it a feasible option for Indian kala-azar.  The preferential pricing agreement with WHO has reduced the price of Liposomal Amphotericin B (AmBisome; ) for endemic regions to $20 per 50-mg vial and this further opens the prospect of combining of Liposomal Amphotericin B in various combination regimens.  Further studies to identify combination therapy with drugs like lipid formulations of amphotericin B, miltefosine and paramomycin are underway with 8-11 days duration of therapy. If successful, this would be a groundbreaking find providing affordable treatment with much improved compliance and prevent the emergence of resistance. The pipeline for the antileishmanial drug is empty, it is imperative that we try and protect and prolong the effective life of the existing drugs.
Monitoring drug resistance
Ideally, parasite resistance should be monitored, rather than relapses or unresponsiveness. It will also permit the identification of key intracellular targets and parasite defense mechanisms, which can then be exploited to rationally develop analogues of existing drugs that would not affected by the most common defenses. Analysis of genetic markers that determine high antileishmanial resistance, performed systematically for every parasite isolate that shows low antileishmanial sensitivity would facilitate the tracking of the level of resistance in affected populations. At present there are no molecular markers of resistance available for the currently used antileishmanial drugs and the only reliable method for monitoring resistance of isolates is the technically demanding in vitro amastigote-macrophage model. Development of drug resistance markers and tools easy to use in the field should be encouraged.
Management of HIV/VL Co-infection
Another potential source for the emergence of drug resistance are the HIV/VL coinfected patients. These patients have high parasite burden, a weak immune response, respond poorly to treatment and have a high relapse rate. Therefore they are the ideal candidates to harbor drug resistant parasites. With the growing burden of HIV in India, HIV/VL coinfection could become a major problem. Experience from Southern Europe shows that initial response to Sb v and conventional amphotericin B is low (~40-65%) in severely immuncompromised persons and severe adverse events are frequent. Initiation of HAART dramatically decreases the incidence of VL coinfection. Therefore; HAART in combination with antileishmanials should be advocated strictly in these patients.
Inventory of antileishmanial drugs is very small, and emergence of drug resistance is further complicating the control of leishmaniasis. A better understanding of mechanism of action of the drugs and unraveling the puzzle of drug resistance mechanisms, with easy to use markers of resistance may pave the way for more rational use of drugs. Combination chemotherapy is rapidly emerging as the norm for treating several infective disorders like malaria, tuberculosis, HIV etc., and its application is strongly advocated for VL. Directly observed therapy given free, in treatment centers manned by trained personnel, will go a long way in controlling the disease as well as drug resistance.
This work was supported by NIAID, NIH TMRC, Grant No. 1P50AI074321-01.
|1||Desjeux P. Human leishmaniases: epidemiology and public health aspects. World Health Stat Q 1992;45:267-75. |
|2||Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India 1999;12:62-8. |
|3||Richens J. Genital manifestations of tropical diseases. Sex Transm Infect 2004;80:12-7. |
|4||Magill AJ. Epidemiology of the leishmaniases. Dermatol Clin 1995;13:505-23. |
|5||Alvar J, Caρavate C, Gutiιrrez-Solar B, Jimιnez M, Laguna F, Lσpez-Vιlez R, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997;10:298-319. |
|6||Desjeux P, Alvar J. LeishmaniaIHIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003;97:3-15. |
|7||Laguna F, Videla S, Jimιnez-Mejνas ME, Sirera G, Torre-Cisneros J, Ribera E, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 2003;52:464-8. |
|8||Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, Caldeira L, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996;32:133-7. |
|9||Alvar J, Gutiιrrez-Solar B, Pachσn I, Calbacho E, Ramνrez M, Vallιs R, et al. AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Clin Dermatol 1996;14:541-6. |
|10||Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann Trop Med Parasitol 2003;97:29-45. |
|11||Cascio A, Colomba C. Childhood Mediterranean visceral leishmaniasis. Infez Med 2003;11:5-10.|
|12||Davidson RN, Di Martino L, Gradoni L, Giacchino R, Russo R, Gaeta GB, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multicentre trial. Q J Med 1994;87:75-81.|
|13||Asilian A, Jalayer T, Nilforooshzadeh M, Ghassemi RL, Peto R, Wayling S, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003;81:353-9.|
|14||el-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992;27:227-31.|
|15||Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskanolari SE, Khatami A et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis. Arch Dermatol 2006;142:1575-79.|
|16||Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004;38:1266-72.|
|17||Ercoli N. Drug responsiveness in experimental cutaneous leishmaniosis. Exp Parasitol 1966;19:320-6.|
|18||Berhe N, Wolday D, Hailu A, Abraham Y, Ali A, Gebre-Michael T, et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 1999;13:1921-5.|
|19||Carson PE. 8-aminoquinolines, In: Peters W, Richards WH, editors. Antimalarial drugs II. Berlin, Germany: Springer-Verlag; 1984. p. 83-121.|
|20||Leyden J. Pharmacokinetics and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol 1998;38:S42-7.|
|21||Al-Jaser M, El-Yazigi A, Croft SL. Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharm Res 1995;12:113-6.|
|22||Allen S, Neal RA. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates. In: Hart DT, editor. Leishmaniasis. New York, NY: Plenum Press; 1998, p.711-20.|
|23||Berman JD. Activity of imidazoles against Leishmania tropica in human macrophage cultures. Am J Trop Med Hyg 1981;30:566-9.|
|24||Neal RA, Allen S, McCoy N, Olliaro P, Croft SL. The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 1995;35:577-84.|
|25||Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992;165:528-34.|
|26||Peters W. The treatment of kala-azar. New approach to an old problem. Indian J Med Res 1981;73:1-18.|
|27||Aikat BK, Sahaya S, Pathania AG, Bhattacharya PK, Desai N, Prasad LS, et al. Clinical profile of cases of kala-azar in Bihar. Indian J Med Res 1979;70:563-70.|
|28||Thakur CP, Kumar M, Singh SK, Sharma D, Prasad US, Singh RS, et al. Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Br Med J (Clin Res Ed) 1984;288:895-7.|
|29||Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Br Med J (Clin Res Ed) 1988;296:1557-61.|
|30||Thakur CP, Kumar M, Pandey AK. Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate. Indian J Med Res 1991;93:103-10.|
|31||Jha TK, Singh NK, Jha SN. Therapeutic use of sodium stibogluconate in kala-azar from some hyperendemic districts of N. Bihar, India. (Abstract) J Assoc Physicians India 1992;40:868.|
|32||Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000;31:1104-7.|
|33||Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon-ά plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis 1997;176:1117-9.|
|34||Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 2003;97:350-4.|
|35||Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999;180:564-7.|
|36||Sundar S, Thakur BB, Tandon AK, Agrawal NR, Mishra CP, Mahapatra TM, et al. Clinico-epidemiological study of drug resistance in Indian kala-azar. BMJ 1994;308:307.|
|37||Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM, Berman JD, et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 1998;59:139-43.|
|38||Laguna F, Videla S, Jimιnez-Mejνas ME, Sirera G, Torre-Cisneros J, Ribera E, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 2003;52:464-8. |
|39||Berman JD, Chulay JD, Hendricks LD, Oster CN. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am J Trop Med Hyg 1982;31:459-65.|
|40||Bryceson AD, Chulay JD, Ho M, Mugambii M, Were JB, Muigai R, et al. Visceral leishmaniasis unresponsive to antimonial drugs. 1. Clinical and immunological studies. Trans R Soc Trop Med Hyg 1985;79:700-4. |
|41||Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, Michel G, et al. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 1997;41:827-30.|
|42||Fairlamb AH, Cerami A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol 1992;46:695-729.|
|43||Vickers TJ, Greig N, Fairlamb AH. A trypanothione-dependent glyoxalase I with a prokaryotic ancestry in Leishmania major. Proc Natl Acad Sci USA 2004;101:13186-91.|
|44||Frezard F, Demicheli C, Ferreira CS, Costa MA. Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrob Agents Chemother 2001;45:913-916.|
|45||Shaked-Mishan P, Ulrich N, Ephros M, Zilberstein D. Novel intracellular Sb-V reducing activity correlates with antimony susceptibility in Leishmania donovani. J Biol Chem 2001;276:3971-6.|
|46||Wyllie S, Cunningham ML, Fairlamb AH. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 2004;279:39925-32.|
|47||Sereno D, Holzmuller P, Mangot I, Cuny G, Ouaissi A, Lemesre JL. Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob Agents Chemother 2001;45:2064-9.|
|48||Sudhandiran G, Shaha C. Antimonial-induced increase in intracellular Ca 2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. J Biol Chem 2003;278:25120-32.|
|49||Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem 2004;73:87-106.|
|50||Shaked-Mishan P, Ulrich N, Ephros M, Zilberstein D. Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J Biol Chem 2001;276:3971-6.|
|51||Zhou Y, Messier N, Ouellette M, Rosen BP, Mukhopadhyay R. Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug Pentostam. J BioI Chern 2004;279:37445-51. |
|52||Denton H, McGregor JC, Coombs GH. Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDRI. Biochem J 2004;381:405-12. |
|53||Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, et al. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 2004;279:31010-7.|
|54||Mukhopadhyay R, Dey S, Xu N, Gage D, Lightbody J, Ouellette M, et al. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci USA 1996;93:10383-7.|
|55||Grondin K, Haimeur A, Mukhopadhyay R, Rosen BP, Ouellette M. Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J 1997;16:3057-65.|
|56||Haimeur A, Guimond C, Pilote S, Mukhopadhyay R, Rosen BP, Poulin R, et al. Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol Microbiol 1999;34:726-35.|
|57||Ouellette M, Legare D, Haimeur A, Grondin K, Roy G, Brochu C, Papadopoulou B. ABC transporters in Leishmania and their role in drug resistance. Drug Resist Updat 1998;1:43-8. |
|58||Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Bioi 1992;8:67-113. |
|59||Callahan HL, Beverley SM. Heavy metal resistance: a new role for P-glycoproteins in Leishmania. J Biol Chem 1991;266:18427-30.|
|60||Ouellette M, Borst P. Drug resistance and P-glycoprotein gene amplification in the protozoan parasite Leishmania. Res Microbiol 1991;142:737-46.|
|61||Legare D, Richard D, Mukhopadhyay R, Stierhof YD, Rosen BP, Haimeur A, et al. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J Biol Chem 2001;276:26301-7. |
|62||El Fadili K, Messier N, Leprohon P, Roy G, Guimond C, Trudel N, et al. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother 2005;49:1988-93.|
|63||Singh N, Singh RT, Sundar S. Novel mechanism of drug resistance in kala azar field isolates. J Infect Dis 2003;188:600-7.|
|64||Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J Assoc Physicians India 1991;39:314-6.|
|65||Jha TK. Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983;77:167-70.|
|66||Nacher M, Carme B, Sainte Marie D, Couppiι P, Clyti E, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2001;95:331-6.|
|67||Soto 1, Buffet P, Grogl M, Berman 1. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am 1 Trop Med Hyg 1994;50:107-11. |
|68||Correia D, Macκdo VO, Carvalho EM, Barral A, Magalhγes AV, de Abreu MV, et al. Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis. Rev Soc Bras Med Trop 1996;29:447-53. |
|69||de Paula CD, Sampaio JH, Cardoso DR, Sampaio RN. A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20 mg Sb V/day for 20 days to treat cutaneous leishmaniasis. Rev Soc Bras Med Trop 2003;36:365-71. |
|70||Amato V, Amato J, Nicodemo A, Uip O, Amato-Neto V, Duarte M. Treatment of mucocutaneous leishmaniasis with pentamidine isothionate. Ann Dermatol Venereol 1998;125:492-5. |
|71||Bray PG, Barrett MP, Ward SA, de Koning HP. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol 2003;19:232-9.|
|72||Basselin M, Denise H, Coombs GH, Barrett MP. Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob Agents Chemother 2002;46:3731-8.|
|73||Coelho AC, Beverley SM, Cotrim PC. Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol Biochem Parasitol 2003;130:83-90.|
|74||Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 1999;93:9-23. |
|75||Mishra M, Biswas UK, lha DN, Khan AB. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992;340:1256-7. |
|76||Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997;127:133-7. |
|77||Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002;66:143-6. |
|78||Berman JD. DS Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999;28:49-51. |
|79||Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998;76:25-32.|
|80||Mbongo N, Loiseau PM, Billion MA, Robert-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother 1998;42:352-7.|
|81||Pourshafie M, Morand S, Virion A, Rakotomanga M, Dupuy C, Loiseau PM. Cloning of S-adenosyl-L-methionine:C-24-∆-sterolmethyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-resistant promastigotes. Antimicrob Agents Chemother 2004;48:2409-14.|
|82||Durand R, Paul M, Pratlong F, Rivollet D, Dubreuil-Lemaire ML, Houin R, et al. Leishmania infantum: lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis. Antimicrob Agents Chemother 1998;42:2141-3.|
|83||Di Giorgio C, Faraut-Gambarelli F, Imbert A, Minodier P, Gasquet P, Dumon H. Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. J Antimicrob Chemother 1999;44:71-6.|
|84||Sundar S, Makharia A, More DK, Agrawal G, Voss A, Fischer C, et al. Short-course miltefosine treatment for visceral leishmaniasis. Clin Infect Dis 2000;31:1110-3.|
|85||Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001;6:928-34.|
|86||Escobar P, Matu S, Marques C, Croft SL. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop 2002;81:151-7.|
|87||Yardley V, Croft SL, De Donker S, Dujardin JC, Siddhartha K, Miranda C, et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 2005;73:272-5.|
|88||Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004;38:1266-72.|
|89||Verma NK, Dey CS. Possible mechanism of miltefosinemediated death of Leishmania donovani. Antimicrob Agents Chemother 2004;48:3010-5.|
|90||Paris C, Loiseau PM, Bories C, Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004;48:852-9.|
|91||P΄erez-Victoria FJ, Castanys S, Gamarro F. Resistance to miltefosine in Leishmania donovani involves a defective inward translocation of the drug. Antimicrob Agents Chemother 2003;47:2397-403.|
|92||Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 2003;278:49965-71.|
|93||Pιrez-Victoria FJ, Sanchez-Canete MP, Castanys S, Gamarro F. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J Biol Chem 2006;281:23766-75.|
|94||Perez-Victoria FJ, Di Pietro A, Barron D, Ravelo AG, Castanys S, Gamarro F. Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents. Curr Drug Targets 2002;3:311-33.|
|95||Seifert K, Matu S, Perez Victoria FJ, Castamys S, Gamarro F, Croft SL. Characterization of Leishmania donovani promastigotes resistant to hexadecylphophocholine (miltefosine). Int J Antimicrob Agents 2003;22:380-87.|
|96||Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007;356:2571-81.|
|97||el-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992;27:227-31. |
|98||Krause G, Kroeger A. Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg 1994;88:92-4. |
|99||el-On J, Hamburger AD. Topical treatment of New and OldWorld cutaneous leishmaniasis in experimental animals. Trans R Soc Trop Med Hyg 1987;81:734-7.|
|100||Neal RA, Allen S, McCoy N, Olliaro P, Croft SL. The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 1995;35:577-84.|
|101||Teklemariam S, Hiwot AG, Frommel D, Miko TL, Ganlov G, Bryceson A. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused byLeishmania aethiopica. Trans R Soc Trop Med Hyg 1994;88:334-9.|
|102||Maarouf M, de Kouchkovsky Y, Brown S, Petit PX, Robert-Gero M. In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp Cell Res 1997;232:339-48.|
|103||Maarouf M, Lawrence F, Croft SL, Robert-Gero M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol Res 1995;81:421-42.|
|104||Maarouf M, Adeline MT, Solignac M, Vautrin D, Robert-Gero M. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite 1998;5:167-73.|
|105||Jhingram A, Chawla B, Saxena S, Barrett MP, Madhubala R. Paromomycin: uptake and resistance in Leishmania donovani. Mol Biochem Parasitol 2009;164:111-7. |
|106||Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, et al. Phase 2 trial of WR6026 an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001;65:685-9.|
|107||Croft SL, Yardley V. Chemotherapy of leishmaniasis. CUIT Pharm Des 2002;8:319-42.|
|108||Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992;165:528-34.|
|109||Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 2005;83:394-5.|
|110||Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, et al. New treatment approach in indian visceral leishmaniasis: single-dose liposomal amphotericin b followed by short-course oral miltefosine. Clin Infect Dis 2008;47:1000-6.|
|111||Olliaro P, Sundar S. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009;14:88-92.|